# A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer

> **NCT04188119** · PHASE2 · WITHDRAWN · sponsor: **The Christie NHS Foundation Trust**

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Avelumab
- **DRUG:** Aspirin
- **DRUG:** Lansoprazole

## Key facts

- **NCT ID:** NCT04188119
- **Lead sponsor:** The Christie NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-12-01
- **Primary completion:** 2024-09-30
- **Final completion:** 2025-05-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Unable to open
- **Last updated:** 2025-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04188119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04188119, "A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04188119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*